Ranexa (Ranolazine) - Summary

RANEXA SUMMARY

Ranexa™
ranolazine extended-release tablets

Ranexa™ (ranolazine) is available as an extended-release tablet for oral administration.

Ranexa is indicated for the treatment of chronic angina. Because Ranexa prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other antianginal drugs. Ranexa should be used in combination with amlodipine, beta-blockers or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than men.

See all Ranexa indications & dosage >>

RANEXA NEWS HIGHLIGHTS

Published Studies Related to Ranexa (Ranolazine)

Metabolic efficiency with ranolazine for less ischemia in non-ST elevation acute coronary syndromes (MERLIN TIMI-36) study. [2008.01]

Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non ST-segment elevation acute coronary syndrome: results from the Metabolic Efficiency With Ranolazine for Less Ischemia in Non ST-Elevation Acute Coronary Syndrome Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial. [2007.10.09]

Safety and efficacy of extended-release ranolazine in patients aged 70 years or older with chronic stable angina pectoris. [2007.07]

Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. [2007.04.25]

Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). [2007.03.13]

more >>

Clinical Trials Related to Ranexa (Ranolazine)

Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes [Completed]

Microvascular Coronary Disease In Women: Impact Of Ranolazine [Recruiting]

Effect of Ranolazine on Echocardiographic Indices of Diastolic Dysfunction [Recruiting]

Ranolazine Versus Placebo Effects on Exercise Tolerance in Patients With Heart Disease and Peripheral Arterial Disease [Not yet recruiting]

An Open-Label, Multi-Center Study Evaluating the Validity, Reliability, and Responsiveness of a New Female-Specific Angina Questionnaire in Women With Chronic Angina Treated With Ranolazine Extended-Release Tablets (CVT 3041) [Recruiting]

more >>